<DOC>
	<DOC>NCT01421277</DOC>
	<brief_summary>This study will describe the reasons for triptan utilization patterns (continuation and discontinuation) in triptan-naïve participants and assess the stability of treatment utilization patterns over time according to standard medical guidelines or clinical practice standards of the investigating physician.</brief_summary>
	<brief_title>Study of Treatment Used for Migraine Headaches (MK-0974-076)</brief_title>
	<detailed_description>After study start, the Protocol was amended to clarifiy that the first triptan prescription must have been received by the participant within a time window of 3 months (± 2 weeks) prior to the participant being identified by the Investigator, and could be enrolled into the study within 6 months of taking the prescribed triptan medication for the first time and that use of a sample triptan would not disqualify a participant as long as the sample was of the same triptan that was eventually prescribed.</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Inclusion criteria: At least 18 years of age in the United States at the time of consent Physiciandiagnosed migraine with or without aura At least two and up to a maximum of 8 moderate to severe migraine attacks during the 30 days prior to screening Initial triptan prescription 3 months (± 2 weeks) prior to being identified as eligible for this study, and triptannaïve before that initial prescription Used triptan medication at least once within 6 months prior to the date of informed consent for screening Internet access and able to complete online surveys via electronic data entry Exclusion criteria: Treated with triptans prior to this study In active litigation and compensation issues including disability dispute cases with a Government agency Participation in a clinical trial within the last 90 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>